Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement

Reuters

06/19

Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement

Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544166075"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544166075\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544166075?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544166075","market":"nz","top_or_hot":-1,"title":"Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-19 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1232","symbol_name":"复合型公用事业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL7kd4mX:1","article_id":"2544166075","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544166075","pubTimestamp":1750332486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1232":"复合型公用事业","BK0188":"融资融券","002393":"力生制药","BK0028":"国家队","00882":"天津发展","BK0239":"医药制造"},"translate_title":"天津发展控股子公司力生制药与兴业银行新协议扩大投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002393":0.9,"00882":0.9},"content_text":"Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    \n\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}